Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22464650 | 0.89 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL22464649 | 0.89 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL27965700 | 0.86 | KMT2A (0.47) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL27965431 | 0.86 | KMT2A (0.47) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL3919240 | 0.84 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL11731029 | 0.82 | CETP (0.41) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL11731022 | 0.82 | CETP (0.41) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL9030769 | 0.81 | CETP (0.43) | — | |
| SCHEMBL9030758 | 0.81 | CETP (0.43) | — | |
| SCHEMBL15319387 | 0.81 | MEN1 (0.37) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522597-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| CN-119638696-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-3921311-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| CN-113661162-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2020163647-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | SLC1A3 4570/4885SLC1A2 4660/4885SLC1A1 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.